Daniel G. Polhamus, Ph.D

Principal Scientist II

Dan joined Metrum in September, 2010 and is an applied statistician with an emphasis on Bayesian biostatistics, clinical trial design, and high performance statistical computing. His dissertation topic was adaptive design for heterogeneous time-to-event data in a Bayesian decision theory framework.

Recent publications by this scientist

Exposure-response analysis of efficacy and safety for pexidartinib in patients with tenosynovial giant cell tumor (TGCT)

October 12, 2021

Yin, O., Zahir, H., French, J., Polhamus, D., Wang, X., van de Sande, M., Tap, W.D., Gelderblom, H., Wagner, A.J., Healey, J.H., Greenberg, J., Shuster, D. and Stacchiotti, S. Exposure-response analysis of efficacy and safety for pexidartinib in patients with tenosynovial giant cell tumor (TGCT). CPT: Pharmacometrics & Systems Pharmacology. Advance online publication. https://doi.org/10.1002/psp4.12712

View More

Population pharmacokinetic analysis of ulotaront in subjects with schizophrenia

July 22, 2021

Galluppi GR, Polhamus DG, Fisher JM, Hopkins SC, Koblan KS. CPT Pharmacometrics Syst Pharmacol. Published online July 22, 2021. doi:10.1002/psp4.12692

View More

Opportunities at the Intersection of Pharmacometrics and Health Economics for Insightful Drug Development Decision Making

March 15, 2021

Marc Gastonguay, Jing Liu, Jean Lachaine, Anna G. Kondic, and Daniel Polhamus.  Presented at the American Society for Clinical Pharmacology (ASCPT) annual meeting, March 15, 2021.

Download PDF